MX368783B - Cristal de allisartan isoproxilo, método de preparación del mismo y composición farmacéutica que lo contiene. - Google Patents
Cristal de allisartan isoproxilo, método de preparación del mismo y composición farmacéutica que lo contiene.Info
- Publication number
- MX368783B MX368783B MX2016017141A MX2016017141A MX368783B MX 368783 B MX368783 B MX 368783B MX 2016017141 A MX2016017141 A MX 2016017141A MX 2016017141 A MX2016017141 A MX 2016017141A MX 368783 B MX368783 B MX 368783B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- crystal
- preparation
- composition containing
- method therefor
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- XMHJQQAKXRUCHI-UHFFFAOYSA-N propan-2-yloxycarbonyloxymethyl 2-butyl-5-chloro-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate Chemical compound CCCCC1=NC(Cl)=C(C(=O)OCOC(=O)OC(C)C)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1 XMHJQQAKXRUCHI-UHFFFAOYSA-N 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Se divulga una forma cristalina de allisartan isoproxilo y una composición farmacéutica de la misma. La forma cristalina no es electrostática, altamente fluida y altamente estable, y se puede utilizar para el tratamiento de hipertensión y enfermedad que complica la misma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410281060 | 2014-06-20 | ||
PCT/CN2015/080914 WO2015192722A1 (zh) | 2014-06-20 | 2015-06-05 | 一种阿利沙坦酯结晶及其制备方法及含有该结晶的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016017141A MX2016017141A (es) | 2017-08-07 |
MX368783B true MX368783B (es) | 2019-10-15 |
Family
ID=54934855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016017141A MX368783B (es) | 2014-06-20 | 2015-06-05 | Cristal de allisartan isoproxilo, método de preparación del mismo y composición farmacéutica que lo contiene. |
Country Status (10)
Country | Link |
---|---|
US (1) | US10100039B2 (es) |
EP (1) | EP3159336B1 (es) |
JP (1) | JP6307634B2 (es) |
KR (1) | KR20170040794A (es) |
CN (1) | CN106188012B (es) |
CA (1) | CA2949155C (es) |
MX (1) | MX368783B (es) |
RU (1) | RU2662816C2 (es) |
TW (1) | TWI532734B (es) |
WO (1) | WO2015192722A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109694369B (zh) * | 2017-10-24 | 2023-02-14 | 深圳信立泰药业股份有限公司 | 阿利沙坦酯盐晶型及含有所述盐晶型的药物组合物 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1338238C (en) * | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
JP2707012B2 (ja) * | 1991-12-06 | 1998-01-28 | キッセイ薬品工業株式会社 | N−tert−ブチル−1−メチル−3,3−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法 |
JP2004175788A (ja) * | 2002-09-13 | 2004-06-24 | Mitsubishi Pharma Corp | 2−アミノ−6−(4−メトキシフェニルチオ)−9−[2−(ホスホノメトキシ)エチル]プリンビス(2,2,2−トリフルオロエチル)エステルの結晶 |
WO2006001266A1 (ja) * | 2004-06-23 | 2006-01-05 | Banyu Pharmaceutical Co., Ltd. | 2-アリールプリン誘導体の製造方法 |
US20070167480A1 (en) * | 2005-12-19 | 2007-07-19 | Sicor Inc. | Pure and stable tiotropium bromide |
CN101024643A (zh) * | 2006-02-20 | 2007-08-29 | 上海艾力斯医药科技有限公司 | 咪唑-5-羧酸类衍生物、制备方法及其应用 |
JP5290190B2 (ja) * | 2006-12-06 | 2013-09-18 | サルブリス・アセット・マネイジメント・カンパニー・リミテッド | イミダゾール−5−カルボン酸誘導体の塩、製造方法及びその医薬組成物 |
CN101195615B (zh) * | 2006-12-06 | 2013-03-27 | 深圳市信立泰资产管理有限公司 | 咪唑-5-羧酸衍生物的盐、制备方法及其药物组合物 |
CN101317842A (zh) | 2007-06-07 | 2008-12-10 | 上海艾力斯医药科技有限公司 | 一种咪唑-5-羧酸衍生物的治疗用途 |
CN101407511B (zh) * | 2007-10-11 | 2013-01-09 | 上海艾力斯生物医药有限公司 | 一种结晶型的咪唑-5-羧酸衍生物 |
CN101596189A (zh) * | 2008-06-05 | 2009-12-09 | 上海艾力斯生物医药有限公司 | 含有咪唑-5-羧酸类衍生物的药用组合物 |
JP2010077070A (ja) * | 2008-09-26 | 2010-04-08 | Tokuyama Corp | イミダゾール誘導体の精製方法 |
JP2011105685A (ja) * | 2009-11-20 | 2011-06-02 | Astellas Pharma Inc | フェネチルアミン化合物の結晶 |
CN102725301B (zh) * | 2010-02-05 | 2015-05-13 | 台湾神隆股份有限公司 | 用于制造和纯化托吡酯的方法 |
CN103012377A (zh) * | 2011-09-27 | 2013-04-03 | 江苏艾力斯生物医药有限公司 | 一种咪唑-5-羧酸酯的重结晶方法 |
WO2013044816A1 (en) * | 2011-09-30 | 2013-04-04 | Sunshine Lake Pharma Co., Ltd. | Crystalline forms of azilsartan and preparation and uses thereof |
CN103193626B (zh) * | 2012-01-10 | 2016-05-11 | 上海天伟生物制药有限公司 | 一种前列腺素类似物的晶型及其制备方法和用途 |
CN103965171A (zh) | 2014-04-30 | 2014-08-06 | 上海艾力斯医药科技有限公司 | 一种阿利沙坦酯的制备方法 |
-
2015
- 2015-05-25 CN CN201510271632.6A patent/CN106188012B/zh active Active
- 2015-06-05 KR KR1020177000498A patent/KR20170040794A/ko active Search and Examination
- 2015-06-05 CA CA2949155A patent/CA2949155C/en active Active
- 2015-06-05 JP JP2016574074A patent/JP6307634B2/ja active Active
- 2015-06-05 RU RU2017101600A patent/RU2662816C2/ru active
- 2015-06-05 WO PCT/CN2015/080914 patent/WO2015192722A1/zh active Application Filing
- 2015-06-05 EP EP15809449.0A patent/EP3159336B1/en active Active
- 2015-06-05 US US15/320,449 patent/US10100039B2/en active Active
- 2015-06-05 MX MX2016017141A patent/MX368783B/es active IP Right Grant
- 2015-06-17 TW TW104119535A patent/TWI532734B/zh active
Also Published As
Publication number | Publication date |
---|---|
CN106188012A (zh) | 2016-12-07 |
KR20170040794A (ko) | 2017-04-13 |
JP6307634B2 (ja) | 2018-04-04 |
US10100039B2 (en) | 2018-10-16 |
RU2662816C2 (ru) | 2018-07-31 |
EP3159336A1 (en) | 2017-04-26 |
JP2017518351A (ja) | 2017-07-06 |
EP3159336A4 (en) | 2017-11-15 |
CA2949155A1 (en) | 2015-12-23 |
EP3159336B1 (en) | 2019-08-07 |
MX2016017141A (es) | 2017-08-07 |
TWI532734B (zh) | 2016-05-11 |
RU2017101600A (ru) | 2018-07-23 |
RU2017101600A3 (es) | 2018-07-23 |
US20170152243A1 (en) | 2017-06-01 |
CA2949155C (en) | 2022-05-31 |
WO2015192722A1 (zh) | 2015-12-23 |
TW201600518A (zh) | 2016-01-01 |
CN106188012B (zh) | 2018-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL269444B (en) | New modified indazoles, methods for their production, pharmaceutical preparations containing the new modified indazoles, and the use of the new modified indazoles in the production of drugs | |
EP3716945A4 (en) | LIQUID DOSAGE FORMS, METHODS OF PREPARATION AND USE | |
MX2020003939A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos. | |
EA201691582A1 (ru) | Новые фармацевтические препараты | |
MY191581A (en) | Anti-pd-1 antibodies | |
EP4282479A3 (en) | Use of pridopidine to treat depression or anxiety | |
PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
MX2019015744A (es) | Composiciones farmaceuticas. | |
EP3195866A4 (en) | Pharmaceutical composition for treating flt3 mutation-positive cancer, flt3 mutant inhibitor, and use of said pharmaceutical composition and said inhibitor | |
EP3156037A4 (en) | Alpha-gel-intermediate composition, and production method for alpha-gel-containing o/w emulsion cosmetic using said composition | |
AU2015299431B2 (en) | Pyrrolidinone derivatives as metAP-2 inhibitors | |
EA201790650A1 (ru) | Лекарственная форма и способы применения абиратерона ацетата | |
NZ730250A (en) | 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators | |
EP3156043A4 (en) | A-gel-intermediate composition, and production method for a-gel-containing o/w emulsion cosmetic using said composition | |
MX2017003216A (es) | Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. | |
MX2017015137A (es) | Composicion farmaceutica oral de dosis diaria de isotretinoin. | |
HK1245794A1 (zh) | 咪唑並噁嗪晶體、含有所述晶體的藥物組合物和製備所述晶體的方法 | |
ZA201703467B (en) | Methods of treating ocular conditions | |
IN2014CH00840A (es) | ||
AU2015303724B2 (en) | Quinazoline derivative | |
EA201691493A1 (ru) | Замещенные n-арилпиридиноны | |
EP3297636A4 (en) | Pharmaceutical composition of carboplatin based co-crystals and use thereof | |
MX2017008090A (es) | Nuevos compuestos, su procedimiento de sintesis y su uso en medicina, asi como en cosmetica. | |
EP3235808A4 (en) | Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same | |
MX2017007596A (es) | Procedimiento para fabricar partículas de resinato de fenilefrina; partículas de resinato de fenilefrina; y uso de las partículas de resinato de fenilefrina en formulaciones farmacéuticas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |